Aurinia Pharmaceuticals Inc. AUPH Open Aurinia Pharmaceuticals Inc. in new tab
Aurinia Pharmaceuticals Inc. Analysis (AUPH)
Is Aurinia Pharmaceuticals Inc. a good investment? Aurinia Pharmaceuticals Inc. (AUPH) is currently trading at 15.60 USD. Market analysts have a consensus price target of 17.00 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 7.07. This relatively low multiple may signal that Aurinia Pharmaceuticals Inc. is undervalued compared to historical market norms.
Earnings Schedule: Aurinia Pharmaceuticals Inc. is expected to release its next earnings report on July 30, 2026. The market consensus estimate for Forward EPS is 1.12.
Investor FAQ
Does Aurinia Pharmaceuticals Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Aurinia Pharmaceuticals Inc.?
Aurinia Pharmaceuticals Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be July 30, 2026. The company currently has a trailing EPS of 2.16.
Company Profile
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Dividends
Historical Split Corporate Actions
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 23, 2013 | 0.020000 |
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion